|
Xconomy
From Amgen’s Seattle and Boston Teams Seek to Boost Biotech Hit Rate 20 to 30 Percent:
miletich—
Joe Miletich is senior vice president of translational sciences at Amgen. Photo by Jamey Stillings.
Underwriters and Partners
Connect with Xconomy
Xconomy’s Most Popular
Xconomy on Demand
Did you miss something? Don't despair…
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
